|
Adverse event
|
FEC arm [cases (%)]
|
PE arm [cases (%)]
|
P value
|
|---|
|
Hematologic
|
|
Neutropenia
|
9 (5.96)
|
17 (11.97)
|
0.031
|
|
Anemia
|
6 (4.00)
|
10 (7.04)
|
0.248
|
|
Thrombocytopenia
|
5 (3.31)
|
7 (4.93)
|
0.485
|
|
Non-hematologic
|
|
Nausea
|
4 (2.64)
|
4 (2.82)
|
0.458
|
|
Vomiting
|
2 (1.32)
|
3 (2.11)
|
0.603
|
|
Diarrhea
|
2 (1.32)
|
4 (2.82)
|
0.951
|
|
Constipation
|
3 (1.99)
|
4 (2.82)
|
0.267
|
|
Hair loss
|
24 (15.79)
|
28 (19.72)
|
0.583
|
|
Dermatitis
|
8 (5.30)
|
11 (7.75)
|
0.395
|
|
Febrile
|
1 (0.66)
|
1 (0.70)
|
0.965
|
|
Fatigue
|
7 (4.64)
|
10 (7.04)
|
0.379
|
|
Hand-foot syndrome
|
6 (3.97)
|
5 (3.52)
|
0.913
|
|
Allergy
|
0 (0.00)
|
1 (0.70)
|
0.143
|
-
FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen
